Skip to main content

CORRECTION article

Front. Pharmacol., 05 October 2022
Sec. Drug Metabolism and Transport
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1039267

Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes

This article is a correction to:

  1. Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes

    1. Read original article
Xu Wang&#x;Xu Wang1†Jingjing Fa&#x;Jingjing Fa1†Yuanjin Zhang&#x;Yuanjin Zhang2†Shengbo HuangShengbo Huang2Jie LiuJie Liu2Junqing GaoJunqing Gao1Lina Xing,Lina Xing1,3Zongjun Liu, Zongjun Liu1,3*Xin Wang Xin Wang2*
  • 1Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China
  • 3Putuo Clinical Medical School, Anhui Medical University, Shanghai, China

A Corrigendum on
Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes

by Wang X, Fa J, Zhang Y, Huang S, Liu J, Gao J, Xing L, Liu Z and Wang X (2022). Front. Pharmacol. 13:950525. doi: 10.3389/fphar.2022.950525

In the published article, there was an error in affiliation 1. Instead of “Department of Cardiology, Central Hospital of Shanghai Putuo District, Shanghai University of Traditional Chinese Medicine, Shanghai, China”, it should be “Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Danshen, rivaroxaban, herb-drug interaction, metabolism, cytochrome P 450 (CYP)

Citation: Wang X, Fa J, Zhang Y, Huang S, Liu J, Gao J, Xing L, Liu Z and Wang X (2022) Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes. Front. Pharmacol. 13:1039267. doi: 10.3389/fphar.2022.1039267

Received: 08 September 2022; Accepted: 21 September 2022;
Published: 05 October 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Wang, Fa, Zhang, Huang, Liu, Gao, Xing, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zongjun Liu, lzj72@126.com; Xin Wang, xwang@bio.ecnu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.